Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.
The authors report a patient with severe secondary progressive MS who responded to mitoxantrone but developed a fatal acute myeloblastic leukemia 15 months after completion of mitoxantrone therapy. Therapy-related acute leukemia (TRAL) in relation with mitoxantrone is rare; this patient was the first case among a cohort of 802 French MS patients treated with mitoxantrone. Nevertheless, this case stresses the need to further evaluate the long-term risk of TRAL in patients with MS who receive mitoxantrone.
Brassat
D
D
Department of Neurology, Hôpital Purpan, Toulouse University Medical Center, Toulouse, France. dbrassat@yahoo.fr
Recher
C
C
Waubant
E
E
Le Page
E
E
Rigal-Huguet
F
F
Laurent
G
G
Edan
G
G
Clanet
M
M
D000328:Adult; D015331:Cohort Studies; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008942:Mitoxantrone / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy*
D008942:Mitoxantrone